© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
EGFR+ Lung Cancer
Adding Pemetrexed and Carboplatin to Gefitinib Doubled PFS in EGFR-Mutant NSCLC
April 09, 2020
The addition of pemetrexed and carboplatin chemotherapy to gefitinib doubled progression-free survival and significantly improved overall survival in patients with non–small cell lung cancer harboring an EGFR mutation compared with gefitinib alone, according to results from a randomized phase III clinical trial.
Icotinib Comparable to Gefitinib for Brain Metastasis of EGFR-Mutated NSCLC
April 08, 2020
Icotinib, an EGFR tyrosine kinase inhibitor, demonstrated similar efficacy to gefitinib as a treatment of brain metastasis in patients with EGFR-mutated non–small cell lung cancer, results from a Chinese retrospective study showed.
FDA Grants Priority Review to BLA for First-Line Nivolumab/Ipilimumab Plus Limited Chemo in NSCLC
April 08, 2020
The FDA has accepted the Biologics License Application for and granted Priority Review to the combination of nivolumab plus ipilimumab with limited chemotherapy as a first-line treatment of patients with metastatic or recurrent non–small cell lung cancer who have no EGFR or ALK genomic tumor aberrations, according to a press release from Bristol Myers Squibb. The Prescription Drug Free User Act target action date is set as August 6, 2020, and the combination was granted Fast Track designation.
Research on Molecular Mutations Guides Use of Targeted Therapies in Lung Cancer
April 08, 2020
In an interview with Targeted Oncology, James A. Reeves, MD, discussed how targeted therapies are being used presently in lung cancer and the potential of these agents in the future.
FDA Grants Pembrolizumab Priority Review for TMB-High Tumors
April 07, 2020
The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.
Treating Patients With EGFR-Mutant Lung Cancer With Targeted Therapies
April 04, 2020
Heather Wakelee, MD, discusses how physicians are treating patients with advanced lung cancer using targeted therapies, such as EGFR tyrosine kinase inhibitors in patients harboring an EGFR mutation.
Evaluating the Role of Molecular Testing in Lung Cancer
April 03, 2020
Nathan A. Pennell, MD, PhD, discusses the role of molecular testing when treating and managing patients with lung cancer. He shares his advice on what to do for patients who need therapy immediately, as well.
Tedopi Vaccine Shows Positive Survival in HLA-A2-Positive Advanced NSCLC
April 02, 2020
The immunotherapeutic vaccine OSE-2101 demonstrated a favorable 12-month survival rate as second- or third-line treatment of patients with HLA-A2-positive advanced non–small cell lung cancer, meeting the primary end point of overall survival in the phase III Atalante 1 study, according to a press release from the drug developer, OSE Immunotherapeutics, Inc.
Chemotherapy Better Than EGFR TKIs for First- and Second-Line Treatment of EGFR Exon 20+ NSCLC
March 31, 2020
Chemotherapy demonstrated superior progression-free survival to multiple EGFR tyrosine kinase inhibitors as first- or second-line treatment of patients with EGFR-mutant exon 20 non–small cell lung cancer. This finding is based on results from the largest real-world study of patients with EGFR exon 20 mutations conducted in China.
Chemotherapy Toxicity Correlates With Nutritional Factors in Solid Tumors
March 30, 2020
An association was found between a lower risk of grade 3 or higher chemotherapy toxicity with higher body mass indexes and normal albumin, a protein made in the liver, levels in older adult patients with solid tumors, according to an analysis of a prospective, multicenter study.